ENSTips
DE

Aubrai, der neue KI-Agent

I asked questions about ENS to a brand new AI specialized in the field of longevity. It bases its answers on a database of 4,000 scientific studies.
This AI is called Aubrai because it is based in part on the research work of Aubrey de Grey’s team, a researcher in the field of longevity.
Here are some of the questions and answers:

Question
What would be your approach to regrowing the turbinates in Empty Nose Syndrome? At a minimum, increase their volume, restore the TRPM8 receptors, and improve blood flow.

Answer
Autologous nasal mucosal stem cells on biocompatible scaffolds could rebuild turbinate architecture systematically. The approach targets all three deficits – volume restoration through tissue engineering, TRPM8 receptor regeneration via native cell populations, and vascular network reconstruction.

While the experimental design is robust (MRI for volume, immunohistochemistry for TRPM8, Doppler for flow), we lack clinical validation. The real challenge isn’t concept but execution – finding optimal scaffold materials and cell sources.

Why aren’t ENT surgeons already trialing this?

Wissenschaftliche Publikationen:
CMV NK Evasion MICA 10.1371/journal.ppat.1004058
Ketogenic Diet Shrinks Vesicles 10.1101/2025.06.04.657883
Roflumilast Blocks Doxorubicin Cardiotoxicity 10.2147/dddt.s269029
Nuclear Retention TERT mRNA 10.1038/s41467-021-23221-w
ER Stress Resilience Mitigates SCA6 10.1101/2025.01.27.635103
Perivascular Spaces White Matter 10.3174/ajnr.a5455
Aging vs Hypertension LV 10.1371/journal.pone.0177404
ReCOGnAIze Detects Cognitive Impairment 10.1101/2025.05.10.25327352

Frage
Welche Strategie würden Sie zur Verjüngung der Schleimhaut bei atrophischer Rhinitis verfolgen?

Answer
Beta-glucan could reprogram macrophages to repair nasal mucosa. It expands reparative macrophage populations and accelerates epithelial regeneration via trained immunity (DOI: 10.1101/2025.05.09.653036). Works in colitis models – why not nose? Time for targeted trials in atrophic rhinitis.

Wissenschaftliche Publikation:
Beta-Glucan Colitis Modulation 10.1101/2025.05.09.653036

Frage
Welche Stammzelltechnologie eignet sich am besten zur Verbesserung der Gesundheit der Nasenschleimhaut bei atrophischer Rhinitis? ADSCs, MSCs oder eine andere Technologie?

Antwort
MSCs zeigen eine überlegene Wanderung zu geschädigtem Nasengewebe – SPION-markierte MSCs zeigten in vivo eine verstärkte Migration zu Schäden am Riechkolben. ADSCs bieten praktische Vorteile: einfachere Entnahme, höhere Ausbeute. Ziehen Sie eine durch SMF verbesserte Verabreichung in Betracht: Magnetisches Targeting verbessert die Lokalisierung von MSCs in der Nasenschleimhaut. Hat schon jemand versucht, vorab Senolytika einzusetzen, um zunächst die geschädigten Zellen zu beseitigen?

Wissenschaftliche Publikationen:
Stress Granules AML Survival 10.1101/2025.01.14.632811
MPI Photothermal Prostate Therapy 10.1101/2025.04.27.650870
microRNA Medulloblastoma Therapy 10.1101/2025.04.25.650572
Young Factors Brain Rejuvenation 10.1126/science.1251141
Fetal Liver HSC Signatures 10.1101/2023.06.01.543314
Engineered HSC iNKT Cells 10.1073/pnas.1424877112
Kompot Single-Cell Phenotyping 10.1101/2025.06.03.657769
Short Telomeres ESC Instability 10.1016/j.stem.2013.01.018

Frage
Welches Peptidspray eignet sich am besten zur Regeneration der Nasenschleimhaut?

Answer
Nasal mucosa regeneration isn’t my primary wheelhouse – we focus on systemic aging damage. That said, the principles matter: you want growth factors (EGF, FGF) plus antimicrobials in any repair cocktail. BPC-157 shows promise in other mucosal tissues. But honestly? Direct stem cell therapy beats peptide sprays for serious regeneration. What damage are you trying to repair?